頁籤選單縮合
題名 | 中草藥應用於癌症治療之市場潛力及發展趨勢=The Market Potential and Development Trend of Chinese Herbal Medicine in Cancer Therapy |
---|---|
作者 | 劉祖惠; Liu, Tsu-hwie; |
期刊 | 中醫藥年報 |
出版日期 | 20121000 |
卷期 | 光碟版1:10 2012.10[民101.10] |
頁次 | 頁328-426 |
分類號 | 413.3 |
語文 | chi |
關鍵詞 | 癌症; 中草藥; 植物藥; 植物新藥; 草本膳食補充品; 市場潛力; 發展趨勢; Cancer; Chinese herbal medicine; Plant derived drug; Botanical drug; Herbal dietary supplement; Market potential; Development trend; |
中文摘要 | 本研究之目的,係由產品分析的角度,探討應用於癌症治療的傳統藥物、植物衍生藥物、植物新藥、及草本膳食補充品(機能性食品)等各類中草藥產品,其產品特性、市場規模、參與廠商、及產業競爭力等層面之分析,以作為國內產官學研各界促進中草藥產業發展的參考。本計畫之執行方式為蒐集、彙整,歸納各類癌症治療中草藥產品之次級資料,就已上市及研發中產品階段,分別進行探討,再導入我國目前產業環境狀況,提出結論與建議。 癌症藥物治療是重要疾病治療領域,2010年全球癌症藥品市場達 560億美元,雖然藥品研發積極投入,仍然存在大量「未滿足的醫療需求」,許多癌症到現在並無有效藥物治療方式。植物衍生抗癌藥物是由天然植物中,篩選具細胞毒殺性質的抗癌成份,分離純化單一物質,作為研究標的,其開發程序等同化學藥物,如長春鹼與紫杉醇等。植物新藥或中藥新藥同樣強調來源為植物,但是以混合物型式存在,此類藥物因法規較新,在市場上仍處於萌芽階段, 2010年取得我國藥証的「懷特血寶」,即為治療癌末病人嚴重疲憊症狀的植物新藥。 由於中國古代並無「癌症」的病名,故沒有直接針對癌症治療開發的傳統中藥製劑,但可以用相關中醫症候所開立的藥方加以治療,並作為發展現代中藥產品的參考。癌症預防或輔助治療的中草藥膳食補充品屬於機能性食品的領域,強調對機體功能的影響,因為不在我國目前制定的功能食品項目內,所以沒有合法產品,其市場在法規面上不存在,現有產品是游走於灰色地帶。 不同種類中草藥產品的發展受到法規與廠商核心能力的雙重影響,以開發植物衍生藥物的潛力市場最大,法規最完備,進入的技術門檻最高,並非我國廠商的強項。植物新藥或中藥新藥所需條件與其類似,但受法規影響,市場不確定性較高。中藥製劑廠在整體產業環境與法規引導下,核心能力較接近機能性食品廠,其新產品研發方向也朝向食品領域延伸,但由於技術門檻低,市場大,競爭眾多。 未來依照現行法規,建議傳統中藥製劑在癌症治療領域朝向二次開發與加強推廣方向發展,補強實證科學與傳統醫藥的關聯性,以漸進式創新,提升產品價值;在中藥新藥或植物新藥發展上,鼓勵挑選在臨床應用上,經評估具有實際療效與安全性的傳統方劑,以組方調整與製程重新開發,加強智財保護,並作為研究素材,為中藥製劑產業取得新產品開發的契機。 |
英文摘要 | The aim of this study is to analyze the usages of traditional Chinese medicine, plant-derived drug, botanical drug and herbal dietary supplement (functional food) in cancer therapeutic area by product characteristics, market potential, and the competitive advantages in Taiwan. The methodology of this study is collecting and analyzing existing data and reports related to various herbal products under global and Taiwan’s industrial environments as research materials in result of final discussion and suggestion. Cancer is a very important therapeutic area; many of cancer patients do not receive effective treatment because of lacking potent drugs. Therefore, the “unmet medical needs” are still exist. Plant-derived cancer drugs are isolated pure compounds originated from plants, which contain toxic anticancer properties, such as vinca alkaloids or paclitaxel. The difference between botanic drug and plant-derived drug is botanic drug consist of mixtures. The market of botanic drugs are in juvenile stage since the regulation is relatively novel. There are not many fixed prescriptions for cancer disease in ancient Chinese medicine; treatments are varied by the symptoms of different patients. Nevertheless the compositions of cancer-related Chinese herbal drugs are valuable sources for modern drug development. Cancer-prevention or adjunctive herbal food is not permitted by law in Taiwan; the market does not exist legally. Although the demands of these kinds of products still exist. Regulation and core competencies are two major factors for the development of Chinese herbal products. Plant-derived drug has the largest market potential, the most comprehensive regulation, and the highest technical requirement, but our industry is not competitive in this area. Botanic drug has similar requirements as plant-derived drug; but more uncertainties on the market side. Under our current industrial environment and regulation, the core competencies of traditional Chinese medicine company are more close to functional food company than to drug company. However, due to low technical requirement and big market, the competition in functional food area is fierce. Under current regulation, the re-development of existing product and promotion are recommended for traditional Chinese medicines in cancer therapeutic area. The relation of scientific evidence and traditional medical theory has to be strengthened to increase product value and innovation. In botanic drug area, traditional prescriptions with actual clinical effect and safety record may be consider as development material for modern drug under application of intellectual properties by composition redesign and process development. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。